mood disorder	be associate with	significant psychosocial
major depressive disorder	become	second lead cause of disability worldwide by 2020
exist pharmacological treatment	target dysfunction in	mood disorder
cognitive function	treatment with	erythropoietin
neural basis	involve	increase in hippocampal volume
molecular mechanism	have	have propose include activation of anti-apoptotic signalling pathway
aim	describe	potential importance of glycogen synthase kinase 3-beta
we	first examine	publish association between EPO administration
cognitive deficit	be in	patient with mood disorder
develop area	use	pharmacogenetic study of epo treatment in patient with mood disorder

